Call 08047308287 84% Response Rate

Send Email

Anti Cancer Tablet And Injection

Our range of products include sandostatin lar octreotide 20mg/30mg injection and piclib palbociclib 125mg tablet.

Sandostatin LAR Octreotide 20mg/30mg Injection

Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
  • Sandostatin LAR Octreotide 20mg/30mg Injection
Get Best Quote
Get Latest Price

Product Brochure

Product Details:
Strength30 mg
Dose / Strength30 mcg/ml
BrandSandostatin LAr 20/30 MG
Dosage FormInjection
Route of AdminIM
CompositionOctreotide Long Acting Release Injection
Packaging TypeVial
Prescription/Non prescriptionPrescription
ManufacturerNovartis
Usage/ApplicationClinical
Treatment TypeAcromegaly, Carcinoid Tumor
Storage2–8°C
Sandostatin LAR Depot (octreotide acetate) is an octapeptide used to treat acromegaly. Sandostatin LAR Depot is also used to reduce flushing episodes and watery diarrhea caused by cancerous tumors (carcinoid syndrome) or tumors called vasoactive intestinal peptide tumors (VIP adenomas).
Yes! I am InterestedRequest A Callback

Piclib Palbociclib 125mg Tablet

Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
  • Piclib Palbociclib 125mg Tablet
Get Best Quote
Get Latest Price

Product Brochure

Product Details:
BrandPiclib 125mg Tablet
FormTablet
Packaging Size1*21 Tablets
CompositionPalbociclib
Prescription/Non prescriptionPrescription
TreatmentHR+,HER2- Locally advanced or Metastatic Breast Cancer
Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.2). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist. 
Yes! I am InterestedRequest A Callback

EXPLORE MORE CATEGORIES

© Speciality Healthcare Solutions. All Rights Reserved (Terms of Use)Developed and managed by IndiaMART InterMESH Ltd.